伊洛前列素1 ng/kg/min持续72小时输注对机械通气COVID-19患者影响的随机对照试验方案摘要
本研究为多中心、随机、双盲、平行组探索性试验,计划纳入80例需机械通气且可溶性血栓调节蛋白>4 ng/ml的成人COVID-19患者,比较伊洛前列素1 ng/kg/min与安慰剂持续72小时输注对肺内皮病的影响。主要终点为28天内无机械通气存活天数,目前正在招募中。
要点
- 研究对象为机械通气且可溶性血栓调节蛋白>4 ng/ml的成人COVID-19患者。
- 干预为伊洛前列素1 ng/kg/min持续72小时输注,对照为生理盐水安慰剂。
- 主要终点是28天内重症监护室内无机械通气存活天数。
核心结论
- 该试验旨在评估伊洛前列素持续72小时输注对机械通气COVID-19患者肺内皮病及无机械通气存活天数的影响,结果尚未报告。
研究设计与样本
- 多中心、随机(1:1)、盲法、平行组探索性试验,在丹麦首都大区五家重症监护室开展。
- 纳入标准:年龄>18岁、确诊COVID-19、需要机械干预、可溶性血栓调节蛋白>4 ng/ml。
- 排除标准包括退出积极治疗、妊娠、对伊洛前列素过敏、30天内参加过本试验或前列环素试验、无法获得知情同意、危及生命的出血、已知严重心力衰竭(NYHA IV级)、疑似急性冠脉综合征。
- 盲法对象包括所有临床医生、患者、研究者、结局评估者及统计学家。
关键数值与推荐
- 干预剂量为伊洛前列素1 ng/kg/min持续输注72小时,对照为生理盐水。
- 主要终点为28天内重症监护室内无机械通气存活天数。
- 纳入要求可溶性血栓调节蛋白>4 ng/ml。
- 方案版本1.4日期为2020年5月25日,招募开始于2020年6月15日,预计招募完成于2021年2月28日,随后随访90天。
- 试验注册号:EudraCT 2020-001296-33(2020年4月3日)和NCT04420741(2020年6月9日)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the effect of continuous infusion of the potential endothelial cytoprotective agent prostacyclin (Iloprost) 1 ng/kg/min vs. placebo for 72 hours on pulmonary endotheliopathy in mechanically ventilated COVID-19 patients. TRIAL DESIGN: A multicenter, randomized (1:1, active: placebo), blinded, parallel group exploratory trial PARTICIPANTS: Inclusion criteria are: Adult patients (>18 years); Confirmed COVID-19 infection; Need for mechanical interventions; Endothelial biomarker soluble thrombomodulin >4ng/ml. EXCLUSION CRITERIA: Withdrawal from active therapy; Pregnancy (non-pregnancy confirmed by patient being postmenopausal (age 60 or above) or having a negative urine- or plasma-hCG); Known hypersensitivity to iloprost or to any of the other ingredients; Previously included in this trial or a prostacyclin trial within 30 days; Consent cannot be obtained; Life-threatening bleeding defined by the treating physician; Known severe heart failure (NYHA class IV); Suspected acute coronary syndrome The study is conducted at five intensive care units in the Capital Region of Denmark at Rigshospitalet, Herlev Hospital, Hvidovre Hospital, Bispebjerg Hospital, Nordsjællands Hospital. INTERVENTION AND COMPARATOR: The patients are randomized to 72-hours continuous infusion of either prostacyclin (Iloprost/Ilomedin) at a dose of 1 ng/kg/min or Placebo (normal saline). MAIN OUTCOMES: Primary endpoint: Days alive without mechanical ventilation in the intensive care units within 28 days RANDOMISATION: The randomisation sequence is performed in permuted blocks of variable sizes stratified for trial site using centralised, concealed allocation. The randomisation sequence is generated 1:1 (active/placebo) using the online randomisation software 'Sealed Envelope' ( https://www.sealedenvelope.com/ ). Once generated the randomisation sequence is formatted and uploaded into Research Electronic Data Capture system (REDCap) to facilitate centralised, web-based allocation according to local written instruction. BLINDING (MASKING): The following are blinded: all clinicians, patients, investigators, and those assessing the outcomes including the statisticians. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): Forty patients are planned to be randomized to each group, with a total sample size of 80 patients. TRIAL STATUS: Protocol version 1.4 dated May 25, 2020. Recruitment is ongoing. The recruitment was started June 15, 2020 and the anticipated finish of recruitment is February 28, 2021 with 90 days follow up hereafter. TRIAL REGISTRATION: Trial registration at clinicaltrialregisters.eu; EudraCT no. 2020-001296-33 on 3 April 2020 and at ClinicalTrials.gov Identifier: NCT04420741 on 9 June 2020 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
引用
- Johansson PI, Bestle M, Søe-Jensen P, et al. The effect of prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours compared to placebo in mechanically ventilated patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020. PMID: 32847626. doi:10.1186/s13063-020-04696-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。